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Results: Seventeen of ninety-one patients (18%) 
received antifunga[ therapy. Eight of these 17 pa- 
tients received empiricatty and etiotogic agents 
were recovered in nine patients. One As- 
persillus spp., two C. albicans and six Candida spp. 
were recovered from four intra-abdomina[ speci- 
mens, three respiratory specimens, one from urine 
and one from brood. Nine of the patients re- 
ceived amphoteMcin B, five received fluconazote 
and three received caspofungin. Four of eight Can- 
dido spp. were found to be resistant to fluconazote 
(>64 mg/L). 
Conclusion: Funga[ infections are important com- 
ptications of river transptantation. Candida spp. are 
stir[ the most commonty isotated funga[ pathogens. 
The most striking finding is the high resistance 
rates against fluconazote, a commonty used drug 
for antifunga[ prophytaxis. Routine antifunga[ sus- 
ceptibitity testing of the funga[ pathogens seems 
to be mandatory in this setting. 
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Objectives: To determine the causative agents of 
urinary tract infections (UTIs) among rena[ trans- 
ptant recipients and to compare the antibiotic 
susceptibitities of Escherichia coli strains isotated 
from compticated community acquired UTIs and 
rena[ transptant recipients. 
Materials and Methods: We evatuated 75 episodes 
of 63 recipients (35 women and 28 men) with 
confirmed UTI who were transptanted during the 
period 1981-2006 at our center. Medica[ records 
of the patients were reviewed retrospectivety. To 
compare the susceptibitity rates of E. coli, 226 
isotates from non-transptant patients with compti- 
cated community-acquired UTIs were atso evatu- 
ated. 
Results: The mean age of the patients was 
36.5 years in the range from 16 to 58 years. White 
52 of the 63 patients had singte episodes, 11 of 
them had more than one. Of them, 6 episodes 
betonging to 3 patients were defined as reinfec- 
tion. Ten episodes (13.3%) occurred in the first 
month fottowing the transptantation, 11 (14.7%) in 
the period of the second month to sixth month 
and 54 (72%) occurred six months after transptan- 
tation. Forty-six (61.3%) of the 75 isotates were 
Escherichia coli, 9 (12%) Nlebsiella pneumoniae, 
4 (5.3%) Klebsiella oxytoca, 4 (5.3%) Enterococ- 
cus spp., 3 (4%) methicittin-sensitive Staphylococ- 
cus aureus, 2 (2.7%) methicittin-resistant S. au- 
reus, 2 (2.7%) Acinetobacter baumanii, 1 (1.3%) 
methicittin-sensitive coagutase-negative staphylo- 
coccus, 1 (1.3%)Proteus mirabilis, 1 (1.3%)Pseu- 
domonas aerusinosa, 1 (1.3%) Salmonella spp., 
1 (1.3%) Enterobacter aerosenes. Among the 
E. coli isotates, ciprofloxacin resistance rates were 
50% (2/4) in the first month after transptanta- 
tion, 75% (6/8) in the period of the second month 
to sixth month, and 32.4% (11/34) 6 months 
after transptantation. The resistance rates of 
trimethopMm/sutfamethoxazote (TMP-SMX) in the 
same time periods were 100% (4/4), 87.5% (7/8), 
and 70.6% (24/34), respectivety. 
Conclusion: E. coli is the most frequentty iso- 
rated organism from UTI in rena[ transptant recip- 
ients. The rates of resistance to TMP-SMX, ampi- 
cittin, gentamicin among E. coli isotated from re- 
nat recipients are significantty higher than those 
in community-acquired compticated UTIs. Prophy- 
tactic TMP-SMX use in rena[ transptant recipients 
provides some protection against UTI and other 
opportunistic infections. However, the increased 
resistance of urinary pathogens to this agent is 
a major concern. Atthough high resistance rates 
of ciprofloxacin against E. coli strains were de- 
termined in this group, it was not found to be 
statisticatty significant. 
22 
Cytomegalovirus Infections in Solid Organ 
Transplant Recipients 
F. Timurkaynak*, O. Kurt Azap, H. Arstan, 
E. Kursun, B. Demirhan, M. Habera[. Baskent 
University, Dept of Clinical Microbiolosy and 
Infectious Disease, Bahcelievler Ankara, Turkey 
Introduction: Cytomesalovirus (CMV) has been 
recognized as one of the most important oppor- 
tunistic pathogens in transptant recipients. The aim 
of this study is to describe the patient character- 
istics, ctinica[ presentations, the diagnostic toots, 
therapeutica[ regimens and outcomes of the CMV 
infections in sotid organ recipients. 
Methods: Patient data were evatuated retrospec- 
tivety. Nineteen CMV infection episodes in 19 sotid 
organ recipients those were fottowed up with 
the diagnosis of CMV infection during the period 
1997-2005 in our transptantation center were in- 
cluded. 
Results: Fourteen of the patients were mate and 
5 were femate. One of the 14 mate patients and 2 
of the 5 femate patients were river recipients and 
